News
16h
GlobalData on MSNAstraZeneca’s AL amyloidosis drug fails to impress in Phase IIIAstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III ...
AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...
11h
Zacks Investment Research on MSNAstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage StudiesAstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...
In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...
We read with great interest the Article by Randall J Bateman and colleagues investigating long-term gantenerumab treatment in dominantly inherited Alzheimer's disease.1 This important work provides ...
We appreciate the opportunity to address the comments by Yangfan Cheng and colleagues, and Sebastian Walsh and colleagues regarding our Article on long-term gantenerumab treatment in dominantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results